Hendershot Investments Inc. acquired a new stake in shares of Zoetis Inc. (NYSE:ZTS – Get Rating) in the 4th quarter, according to its most recent 13F filing with the SEC. The fund acquired 912 shares of the company’s stock, valued at approximately $222,000.
Other hedge funds and other institutional investors have also made changes to their positions in the company. Investment Research & Advisory Group Inc. acquired a new stake in Zoetis during the 4th quarter valued at approximately $26,000. Account Management LLC acquired a new stake in Zoetis during the 4th quarter valued at approximately $2,715,000. Financial Management Professionals Inc. acquired a new stake in Zoetis during the 3rd quarter valued at approximately $25,000. Amplius Wealth Advisors LLC acquired a new position in shares of Zoetis in the 4th quarter valued at $31,000. Finally, Consolidated Planning Corp acquired a new position in shares of Zoetis in the 3rd quarter valued at $28,000. Institutional investors and hedge funds own 90.36% of the company’s stock.
Several equities analysts recently issued reports on the stock. StockNews.com upgraded shares of Zoetis from a “buy” rating to a “strong-buy” rating in a research note on Friday. Zacks Investment Research cut shares of Zoetis from a “buy” rating to a “hold” rating and set a $242.00 target price for the company. in a research note on Saturday, January 8th. Finally, Citigroup decreased their target price on shares of Zoetis from $232.00 to $208.00 and set a “neutral” rating for the company in a research note on Wednesday, March 9th. Four equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $224.78.
NYSE ZTS traded down $4.49 during trading hours on Monday, hitting $182.81. 1,856,783 shares of the company’s stock traded hands, compared to its average volume of 2,500,819. The company has a market capitalization of $86.25 billion, a PE ratio of 42.81, a PEG ratio of 3.17 and a beta of 0.77. The company has a debt-to-equity ratio of 1.45, a current ratio of 3.86 and a quick ratio of 2.79. Zoetis Inc. has a 52-week low of $165.22 and a 52-week high of $249.27. The firm’s 50-day moving average is $192.30 and its 200-day moving average is $207.28.
Zoetis (NYSE:ZTS – Get Rating) last announced its quarterly earnings data on Tuesday, February 15th. The company reported $1.00 EPS for the quarter, topping the Zacks’ consensus estimate of $0.96 by $0.04. The firm had revenue of $1.97 billion for the quarter, compared to the consensus estimate of $1.93 billion. Zoetis had a return on equity of 50.71% and a net margin of 26.20%. The firm’s revenue was up 8.9% compared to the same quarter last year. During the same quarter last year, the business posted $0.91 earnings per share. Equities research analysts predict that Zoetis Inc. will post 5.15 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Wednesday, June 1st. Stockholders of record on Thursday, April 21st will be issued a dividend of $0.325 per share. The ex-dividend date of this dividend is Wednesday, April 20th. This represents a $1.30 dividend on an annualized basis and a dividend yield of 0.71%. Zoetis’s dividend payout ratio is currently 30.45%.
Zoetis Company Profile (Get Rating)
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
- Get a free copy of the StockNews.com research report on Zoetis (ZTS)
- Banking On Bank Of America
- Major Shareholder Bets Big On Nielson Holdings plc
- Tapestry Stock is a Value Play Down Here
- Levi Straus Stock Ready to Buy the Dip
- Bed Bath & Beyond Stock Ready to Scale Into
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.